LPTX Leap Therapeutics Inc.

5.58
+0.04  (1%)
Previous Close 5.54
Open 5.51
Price To book 2.86
Market Cap 52429234
Shares 9,395,920
Volume 11,200
Short Ratio 1.12
Av. Daily Volume 24,527

SEC filingsSee all SEC filings

  1. 8-K - Current report 171022948
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171022935
  3. 8-K - Current report 17923511
  4. 8-K - Current report 17836390
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17836377

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASCO June 3, 2017. Abstract 4075.
DKN-01
Biliary tract cancer (BTC)
Phase 1/2 enrolling as of January 2017.
DKN-01
Esophageal cancer
Phase 3 data fail October 2015
CureXcell
Diabetic Foot Ulcers
Phase 3 endpoint not expected to be met - August 19, 2015.
CureXcell
Venous Leg Ulcers